This is a news story, published by MSN, that relates primarily to Medicare news.
For more health policy news, you can click here:
more health policy newsFor more news from MSN, you can click here:
more news from MSNOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about health policy, you might also like this article about
drug price negotiations. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Medicare news, costliest prescription drugs news, news about health policy, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Medicare negotiationsReuters
•
80% Informative
The pharmaceutical industry is pushing to revamp the law that allows Medicare to negotiate prices for its costliest prescription drugs.
Seven lobbyists and executives who work with top pharmaceutical and biotech companies told Reuters they are pushing to delay the timeline under which medications become eligible for price negotiations by four years .
Two sources said the industry is already speaking directly with members of the Trump transition team.
Medicare covers 66 million Americans , mostly aged 65 and older .
VR Score
90
Informative language
95
Neutral language
75
Article tone
formal
Language
English
Language complexity
64
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links